Gathering the record
Relay is organizing the evidence and source boundaries.
Long-acting balanced glucagon / GLP-1 dual receptor agonist peptide
An experimental drug being studied for weight loss and fatty-liver disease.
Evidence is explained by question. Dosing references show their own check dates.
60-second overview
Why people look into it, what studies found, and what is still unknown.
Educational information only. Evidence reviewed through July 31, 2026. Published studies, sponsor announcements, and trials without results are labeled separately. Evidence gaps apply to the specific finding beside them.
Research questions
Each label shows how much evidence supports that question.
What studies show
Randomized Phase 2 and Phase 2b studies with liver MRI, biopsy, body-weight, metabolic, and safety endpoints, including a published 212-participant MASH trial.
Its EuPort conjugation is intended to prolong exposure while retaining both receptor activities.
This is direct biopsy-based human evidence for liver disease activity.
The negative co-primary result prevents describing the trial as a confirmed antifibrotic success.
MRI-PDFF, liver enzymes, body weight, and lipid markers moved in favorable directions.
The weight signal is human and randomized, though the candidate is no longer positioned only as an obesity drug.
Active trials do not yet demonstrate reduced drinking or improved liver outcomes.
Clinical-trial product handling cannot validate research-market vials.
Risks & unknowns
Relay has not verified a clear pattern of side effects for this compound.
Evidence boundaryHuman exposure is present, but the record is not detailed enough to characterize a reliable adverse-event pattern.
The available information does not reliably show how often particular side effects occur.
Evidence boundaryUnder-detected or under-reported events must not be described as rare.
Relay has not verified which side effects led people to stop treatment in studies.
Evidence boundaryThis is an evidence gap, not proof that discontinuations did not occur.
Relay has not verified a compound-specific warning summary for this profile.
Evidence boundaryInvestigational; Phase 3 MASH planning and active liver-disease research Whether MASH resolution translates into reproducible fibrosis improvement and clinical liver outcomes, plus long-term cardiovascular safety, durability, and Phase 3 benefit-risk.
This profile does not contain verified, product-specific emergency instructions.
Evidence boundaryRelay does not infer emergency guidance from study discontinuations, mechanism, or incomplete adverse-event reporting.
Dosing references
Each table labels its source and applies only to the named route, product, or study. An online example or community report is not an approved dose.
Amounts reported in a human study. A studied amount is not automatically an approved dose or a recommendation for an individual.
IMPACT studied biopsy-confirmed MASH with F2 or F3 liver fibrosis.
| Stage / period | Amount in source | Frequency |
|---|---|---|
| 24-week reported analysis; 48-week trial | 1.2 or 1.8 mg | Once weekly, without titration |
These separate groups were studied for liver disease. They are not an inferred general weight-loss schedule. The 24-week analysis did not meet the fibrosis-improvement primary endpoint.
Pemvidutide · IMPACT Phase 2b, 24-week results Primary article · Methods / interventionThis reference checked Oct 20, 2026. The full-profile review date is shown at the top.This source does not establish a mixing volume or storage period for independently sourced powder. Use formulation-specific instructions; the study amount alone is not a reconstitution recipe.
Concentration = total mass ÷ final volume. The calculator performs user-entered math; it does not choose a dose or diluent.
Open concentration calculatorStarting dose: the amount used at the beginning of the named label schedule or trial.
Maintenance: the ongoing amount described by that product label.
Trial target: the amount assigned to a study group. Different groups may stop increasing at different targets.
A published biopsy-based trial evaluated pemvidutide in adults with MASH and moderate or advanced liver fibrosis.
Population: Adults with biopsy-confirmed MASH and F2/F3 fibrosis, with or without diabetes
Design: Randomized, double-blind, placebo-controlled biopsy trial
Mechanisms
Pemvidutide (ALT-801) is a balanced 1:1 glucagon/GLP-1 receptor dual agonist conjugated to a lipid-like EuPort domain for prolonged exposure. Controlled MASLD research demonstrated large reductions in liver fat, body weight, and markers of hepatic inflammation. In the 212-participant IMPACT Phase 2b biopsy trial, pemvidutide met the primary endpoint of MASH resolution without worsening fibrosis at 24 weeks, but did not significantly meet the co-primary fibrosis-improvement endpoint. Forty-eight-week noninvasive markers reported by the sponsor supported continued antifibrotic investigation. The MOMENTUM obesity program showed substantial weight reduction but was Phase 2. Phase 3 MASH development is planned, while alcohol-use and alcohol-associated-liver-disease studies are ongoing. No regulatory approval or completed clinical-outcomes evidence exists.
A plausible mechanism can explain why a study was attempted. It does not prove that the compound improves a human outcome.
Research reference
A reference for the studies, populations, and routes behind this profile.
Randomized Phase 2 obesity and liver studies include MRI and biopsy endpoints.
Research depth describes how large and mature the overall record is. It does not tell you whether the results were positive.
Weight, liver-fat, and MASH-resolution signals are controlled; fibrosis and clinical outcomes remain unconfirmed.
Confidence describes how reliable and consistent the conclusions are. It can be high for one outcome and low for another.
The strongest evidence type shows what the best-supported conclusions are actually based on.
Human findings are more directly relevant than animal or laboratory results, but they still apply only to the populations and outcomes studied.
Route-specific record
These are exposures used in cited research for a specific route and population—not an instruction for an individual.
Half-life describes how long it takes the measured amount in the body to fall by half. It is not a dosing recommendation.
Evidence can change by administration method. Findings from one route should not automatically be applied to another.
Evidence boundary: MASH resolution improved, but the separate fibrosis-improvement endpoint was not statistically significant. Imaging and short follow-up cannot establish fewer clinical liver events, approval, or independent-product equivalence. Amounts shown describe cited research exposure—not a dosage recommendation.
Studies
Study arms are reported for transparency. They describe what researchers did in a defined record and do not transfer across identities, routes, formulations, or populations.
A later trial phase can ask a more mature question, but it does not guarantee a positive result, regulatory approval, or relevance outside the studied population.
Randomized, double-blind, placebo-controlled biopsy trial
Adults with biopsy-confirmed MASH and F2/F3 fibrosis, with or without diabetes
Pemvidutide met the MASH-resolution primary endpoint but did not significantly improve the co-primary fibrosis endpoint at 24 weeks.
Study administration: Once-weekly pemvidutide 1.2 mg, 1.8 mg, or placebo
Limitations: The positive and negative co-primary findings must be presented together; noninvasive 48-week markers cannot substitute for a confirmatory biopsy or clinical outcomes.
Randomized, placebo-controlled MASLD trial
Adults with metabolic dysfunction-associated steatotic liver disease
Pemvidutide produced large dose-related liver-fat reductions along with weight and metabolic-marker improvements.
Study administration: Multiple once-weekly pemvidutide doses or placebo
Limitations: MRI liver fat and enzymes are surrogate measures and do not establish fibrosis regression or fewer clinical liver events.
Diet-induced obesity and liver-disease animal models
Rodent metabolic models
ALT-801 reduced body weight and liver-related metabolic measures in preclinical models.
Study administration: ALT-801 versus control conditions
Limitations: Animal metabolic effects do not establish human clinical outcomes or safety.
Randomized, double-blind, placebo-controlled obesity trial
Adults with obesity or overweight
MOMENTUM demonstrated substantial mean weight reduction and improvements in selected cardiometabolic markers.
Study administration: Once-weekly pemvidutide dose groups or placebo
Limitations: The full peer-reviewed obesity report was not identified in the same depth as the liver publications; sponsor-reported estimates require that boundary.
Randomized trial in alcohol use disorder
Adults with alcohol use disorder and obesity or overweight
RECLAIM is testing a new indication beyond MASH and obesity.
Study administration: Pemvidutide or placebo
Limitations: No completed efficacy results were available at the cutoff.
Community
Built by the community
Every structured report adds useful context about research setup, outcomes, and unwanted effects as the community dataset grows.
Publicly anonymous by default. Your account keeps reports editable and helps reduce duplicate submissions.Sources
2026-07-31
2025-11-11 · PMID 41237796
2025-10-01 · PMID 41113119
2025-05-30 · NCT06987513
2025-01-01 · PMID 39002641
2023-08-15 · NCT05989711
2022-04-01 · PMID 35461369
2022-03-29 · NCT05295875